Compare GRPN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | NVCR |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 654.9M | 1.3B |
| IPO Year | 2011 | 2015 |
| Metric | GRPN | NVCR |
|---|---|---|
| Price | $17.83 | $12.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $31.25 | $28.42 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $496,093,000.00 | ★ $642,269,000.00 |
| Revenue This Year | $4.17 | $9.75 |
| Revenue Next Year | $10.63 | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $9.21 | $10.70 |
| 52 Week High | $43.08 | $34.13 |
| Indicator | GRPN | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 50.47 |
| Support Level | $16.47 | $10.79 |
| Resistance Level | $17.08 | $11.86 |
| Average True Range (ATR) | 0.92 | 0.59 |
| MACD | 0.32 | 0.06 |
| Stochastic Oscillator | 70.34 | 65.00 |
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.